Comparison of the accuracy of the hemocue glucose analyzer with the Yellow Springs Instrument glucose oxidase analyzer, particularly in hypoglycemia

Alexander D M Stork, Hans Kemperman, D Willem Erkelens and Thiemo F Veneman

Department of Internal Medicine and Metabolic Diseases and 1Department of Clinical Chemistry, University Medical Center Utrecht, Utrecht, The Netherlands and 2Department of Internal Medicine, Twenteborg Hospital, Almelo, The Netherlands

(Correspondence should be addressed to A D M Stork, University Medical Center Utrecht, Department of Internal Medicine and Metabolic Diseases, 31 Puttershof, 3451 LC Vleuten, The Netherlands; Email: adm.stork@hccnet.nl)

Abstract

Objective: We aimed to assess the accuracy of the HemoCue Beta-glucose analyzer (HemoCue) and its correlation with the Yellow Springs Instrument (YSI 2300 STAT; YSI) glucose oxidase analyzer, in particular for hypoglycemic values.

Design and methods: Samples were taken from 24 volunteers during hyperinsulinemic glucose clamp studies. Glucose concentrations were determined immediately with the HemoCue in whole blood and with the YSI in plasma from the same sample. After correction for the difference between whole blood and plasma, the paired plasma glucose concentrations were analyzed with various statistical methods.

Results: A total of 500 paired glucose values were obtained, 209 of which were in the hypoglycemic range. Mean ± S.E. values were 4.85 ± 0.004 mmol/l for the HemoCue (range 1.87 – 16.17) and 4.81 ± 0.004 mmol/l for the YSI (range 1.88 – 15.00; P = 0.80). In the hypoglycemic region, values were 3.26 ± 0.004 mmol/l for the HemoCue (range 1.87 – 5.17) and 3.22 ± 0.003 mmol/l for the YSI (range 1.88 – 4.20; P = 0.59). Regression analyses were HemoCue = 1.019(YSI) – 0.0577 mmol/l, with r = 0.9787 for all values; for hypoglycemic values the HemoCue = 1.1169(YSI) – 0.3393 mmol/l, with r = 0.8798. Using Altman’s residual plot, the difference was 0.03 ± 0.0009 mmol/l, with 18 (3.6%) paired values outside the 95% limits of agreement (−0.82 to 0.89 mmol/l). In the hypoglycemic range, the difference was 0.04 ± 0.001 mmol/l, with six (2.9%) values outside the 95% limits of agreement (−0.71 to 0.79 mmol/l). In error grid analysis, one value was in zone D (0.2%) and five values (1%) were in zone B; 98.8% were within zone A.

Conclusions: Determination of glucose with the HemoCue system had very good correlation with the YSI system in a broad range of glycemia and also for hypoglycemic values. We believe that these methods can be used interchangeably for research and clinical purposes in adults.
required, e.g. during glucose clamps. Although quick and proven to be sufficiently accurate in a large range of glycemia, including low values, there are certain disadvantages to the glucose oxidase method, as employed for example in the Yellow Springs Instrument 2300 STAT (YSI). The analyzers are relatively large and non-portable, and interference and technical malfunction can easily occur, they require careful maintenance and can only be operated by trained technicians. The HemoCue Beta-glucose analyzer (HemoCue) is an instrument that uses a dual wavelength photometer to measure glucose in hemolyzed whole blood after a modified glucose dehydrogenase reaction. Because it is portable, it can be used pre-analytically and at the bedside. It requires very little maintenance, its operation is simple and technical malfunction rarely occurs. In previous research, the accuracy of the HemoCue system has been compared with several reference methods. In some studies (20–29) accuracy compared well, whereas in other studies considerable differences were found between HemoCue measurements and the reference method (5–7, 30–36). However, several confounding factors could have played a role in the variable results. We aimed to assess the accuracy of the HemoCue and its correlation with the YSI, in particular for hypoglycemic glucose values, using various statistical methods, and correcting for potential biases.

**Materials and methods**

Samples were taken from 24 volunteers (14 male and ten female, mean age 43.8 years, range 29.3–67.4), participating in a hyperinsulinemic glucose clamp study that was performed for other purposes. None of the subjects had triglyceride levels >3 mmol/l or used ascorbic acid. Average hematocrit was 0.43 (range 0.38–0.51). During the hyperinsulinemic glucose clamp studies, two antecubital veins were cannulated. Insulin and glucose were infused via one cannula. Blood samples from the second cannula in the other arm were arterialized, using a heating sleeve to warm the arm to 55°C. When withdrawing blood, the first 2 ml were discarded, and immediately thereafter a sample of approximately 1 ml was drawn for analysis. From this sample, a small amount was placed on a sample glass for immediate analysis with a HemoCue β-glucose system (HemoCue AB, Angelholm, Sweden). As plasma glucose concentrations were required for the clamp studies, the remainder of the blood sample was put into a vial and immediately centrifuged for 15 s at 5800 g. Subsequently, the glucose level in plasma was analyzed with a glucose oxidase method (YSI 2300 STAT; Yellow Springs Instruments, Yellow Springs, OH, USA). Both instruments were maintained according to the manufacturers’ recommendations. Additionally, the YSI was calibrated at the start of every day and after every five samples or a maximum of half an hour, whereas the calibration of the HemoCue was checked before every session with the manufacturer’s control cuvette. In addition, the HemoCue’s microcuvettes were stored and handled according to the manufacturer’s recommendations.

**Statistical analysis**

Mean values were calculated and regression analysis was performed. Subsequently, before further analysis the HemoCue results were corrected for the difference in glucose concentration between whole blood and plasma (HemoCue plasma = 1.10 (HemoCue whole blood)). Plasma glucose concentrations of < 4.2 mmol/l in the reference method were considered hypoglycemic, in accordance with the guidelines for the blood glucose monitoring systems of the International Organization for Standardization (ISO) (37). This does not necessarily correlate with clinical hypoglycemia. Several different statistical methods were applied to these paired plasma glucose values, analyzing all paired values, as well as the hypoglycemic values separately (plasma glucose in YSI ≤ 4.2 mmol/l):

(a) mean values; (b) regression analysis; (c) two-tailed Student’s t-test on mean values of HemoCue and YSI with levels of significance defined as P < 0.05; (d) percentage of HemoCue values within 5, 10, 15, 20 and 30% and within 0.2, 0.5, 0.83, 1.0 and 1.5 mmol/l of the YSI value respectively; (e) difference between the HemoCue value and the YSI value plotted against the average of the paired values, according to Altman’s residuals method (38); (f) error grid analysis (15). Data are presented as means±S.E. unless otherwise indicated.

**Results**

A total of 500 paired glucose values were obtained, 209 of which were considered hypoglycemic (plasma glucose on YSI ≤ 4.2 mmol/l).

Mean HemoCue whole blood glucose was 4.41±0.004 mmol/l (range 1.7–14.7), mean YSI plasma glucose was 4.81±0.004 mmol/l (range 1.88–1500; P = 0.001). For the hypoglycemic samples, mean HemoCue whole blood glucose was 2.96±0.003 mmol/l (range 1.7–4.7), mean YSI plasma glucose was 3.22±0.003 mmol/l for YSI (range 1.88–4.20; P < 0.0001). Regression analysis showed the following relationship: HemoCue whole blood = 0.926×(YSI) − 0.0525 mmol/l, with r = 0.9787.

After correcting the HemoCue values for the difference between whole blood and plasma glucose concentration, there was no significant difference between the mean values of HemoCue and YSI plasma glucose concentration (4.85±0.004 vs 4.81±0.004 mmol/l; P = 0.80). The relationship with regression analysis
between these values was HemoCue = 1.019(YSI) − 0.0577 mmol/l, with $r = 0.9787$ (Fig. 1). In the hypoglycemic region, mean value after correction was $3.26 \pm 0.004$ mmol/l for HemoCue (vs $3.22 \pm 0.003$ mmol/l for YSI; ($P = 0.59$)). Regression analysis for the hypoglycemic region yielded HemoCue = 1.1169(YSI) − 0.3393 mmol/l, with $r = 0.8798$ (Fig. 1). The paired plasma glucose values after 10% correction of the HemoCue whole blood results to HemoCue plasma glucose results were used for further analysis.

The percentage of HemoCue plasma values within relative and absolute margins of the paired YSI values are shown in Table 1. As expected, when all values were considered there were significantly higher percentages within the relative margins mentioned than when only hypoglycemic values were considered. However, there were no significant differences in the percentages of values within the absolute margins, although there was a trend towards higher percentages of hypoglycemic values within the absolute margins.

The plot of the individual differences between YSI and HemoCue against the average of the two measurements showed a difference of $0.03 \pm 0.0009$ mmol/l. For 18 (3.6%) paired values the difference was outside the 95% limits of agreement ($−0.82−0.89$ mmol/l). Plotting the individual differences in the hypoglycemic range showed a difference of $0.04 \pm 0.001$ mmol/l. Six (2.9%) were outside the 95% limits of agreement ($−0.71−0.79$ mmol/l) (Fig. 2). When using error grid analysis with YSI values as the reference method, all hypoglycemic HemoCue values except one (99.5%) were within the clinically accurate zone A (Fig. 3). Of the values 1.4% were in zone D, possibly leading to a dangerous failure to detect and treat. When plotting all values on the error grid, the same one value was in zone D (0.2%) and five values (1%) were in zone B, the zone with benign estimate errors. Of all HemoCue values, 98.8% were within zone A (Fig. 3).

**Discussion**

To our knowledge, this is the largest series of paired glucose determinations with the HemoCue system described in the literature, especially for hypoglycemic values. The YSI glucose analyzer, a glucose oxidase system, is currently most frequently used when direct
and accurate determination of glucose concentration is
needed, but carries disadvantages in certain situations.
We have therefore compared the accuracy of the Hemo-
Cue β-glucose system with the frequently used and
well-established YSI 2300 STAT. The HemoCue
measures glucose in whole blood after hemolysis,
rather than in plasma. However, in research and in
most clinical situations, plasma glucose concentrations
are generally described. As glucose concentration in
plasma is approximately 10–15% higher than in
whole blood, depending on the hematocrit and the
method of whole blood analysis (39, 40), we applied
a conversion factor (1.10) to the paired values before
further analysis. This resulted in mean values that
were very similar and not statistically significantly
different, and in a regression slope very close to 1.
Naturally, the correction had no effect on correlation
(r = 0.9787). Our finding that correlation was higher
in the whole range (1.9–15.0 mmol/l) than in the
hypoglycemic range (1.9–4.2 mmol/l) was not surpris-
ing, as relative margins increase at lower glucose levels,
and the coefficient of variation is higher in the lower
range of virtually every laboratory test. This effect
was enhanced by the fact that the HemoCue displays
the result to only one decimal place, whereas the YSI
gives three decimal places. It is of note that the relation-
ship between the two methods appeared not to be uni-
form across the whole range of glucose concentrations.
In the lower range, agreement was very close but, for
values over 8 mmol/l and particularly over 11 mmol/l,
there was a tendency towards higher results of the
HemoCue at higher concentrations. Indeed, this trend
can also be observed in some previous studies (5, 22,
30), although it is not clearly present in other studies
(13, 24). Because the number of measurements is rela-
tively small, the implications are unclear.
We found very small absolute differences between the
mean values of HemoCue and YSI, both for all values, in a
range from 1.9 to 15.0 mmol/l, and in the hypoglycemic
range, which were not statistically significant. However,
one has to be aware of the relatively low discriminative
power of this test. A more discriminative method of com-
parison is plotting the differences between the standard
method and the test method against the average of the
two measurements, according to Altman’s residuals

Table 1 Percentage of HemoCue plasma values within the
margins of the YSI value.

<table>
<thead>
<tr>
<th>Margin</th>
<th>Hypoglycemic values (%)</th>
<th>All values (%)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Relative</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>± 5%</td>
<td>29.2</td>
<td>37.8</td>
<td>0.029</td>
</tr>
<tr>
<td>± 10%</td>
<td>56.9</td>
<td>67.4</td>
<td>0.0079</td>
</tr>
<tr>
<td>± 15%</td>
<td>79.9</td>
<td>87.4</td>
<td>0.01</td>
</tr>
<tr>
<td>± 20%</td>
<td>92.8</td>
<td>96.0</td>
<td>0.075</td>
</tr>
<tr>
<td>± 30%</td>
<td>99.0</td>
<td>99.4</td>
<td>0.61</td>
</tr>
<tr>
<td>Absolute</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>± 0.2 mmol/l</td>
<td>35.9</td>
<td>32.2</td>
<td>0.34</td>
</tr>
<tr>
<td>± 0.5 mmol/l</td>
<td>79.9</td>
<td>75.0</td>
<td>0.16</td>
</tr>
<tr>
<td>± 0.83 mmol/l</td>
<td>99.0</td>
<td>96.4</td>
<td>0.053</td>
</tr>
<tr>
<td>± 1.0 mmol/l</td>
<td>99.0</td>
<td>97.8</td>
<td>0.26</td>
</tr>
<tr>
<td>± 1.5 mmol/l</td>
<td>100</td>
<td>98.8</td>
<td>0.51</td>
</tr>
</tbody>
</table>

Figure 2 Altman’s residual plot (mean of paired
values plotted against the absolute difference
between paired values), with 95% limits of
agreement (means ± 1.96 s.d.; broken lines) and
regression line. In the upper panel,
Altman’s residual plot of all values (open circles)
is shown. For 18 (3.6%) paired values, the
difference was outside the 95% limits of agree-
ment (−0.82 to 0.89 mmol/l). The lower panel
shows the plot of the hypoglycemic values
separately (YSI ≤ 4.2 mmol/l; solid circles). Six
(2.9%) were outside the 95% limits of
agreement (−0.71 to 0.79 mmol/l).
method (38). In the current study, approximately 97% of all paired measurements were within the 95% limits of agreement, and also when hypoglycemic values were considered separately. Therefore, the two methods considered in this study agree sufficiently to be used interchangeably (41). Considering these data, one also has to bear in mind that there is no universally agreed reference methodology for blood glucose measurement. All methods used in clinical laboratories and in research show some inaccuracy and variation when compared with each other or to isotope dilution mass spectrometry (17, 29).

The criteria recommended by the ADA for home blood glucose measuring devices, stating that all the glucose results of a device should be within 5% of the reference values (42), have not been met. Considering the discussion on reference values mentioned above, these criteria are very stringent. The International Organization for Standardization (ISO) is more lenient. It proposes that 95% of measurements should be within ±20% of the reference method, or within 0.83 mmol/l for values ≤ 4.2 mmol/l (37). In this study, the ISO criteria, with YSI as a reference method, are amply met (98.3 and 99.0% respectively). The recommended criteria of both organizations, however, concern home blood glucose measurements, not laboratory devices.

Error grid analysis was developed by the research group of Cox and Clarke to determine the clinical accuracy of glucose results, taking into account both the difference between the reference and the test method values, and the pertinence of the treatment decision resulting from the test method value (15, 43). According to this analysis, only a single HemoCue measurement (0.2%) could potentially have led to a dangerous failure to detect and treat hypoglycemia, and five (1.0%) measurements could have resulted in benign estimation errors. All other measurements (98.8%) were clinically acceptable. Taking into account the large sample size, these results were clinically very satisfactory.

As mentioned in the Introduction, there has been discussion in the literature about the accuracy of the HemoCue blood glucose measuring device (5–7, 20–36). Several confounding factors could have played a role in the variable results. Sample handling and preservation could have biased the results of certain studies, as samples for HemoCue and for the reference method were handled differently. Determination of glucose concentration at different times after withdrawal of
blood allows for pre-analytical glucose usage by cells, even when the blood is stored in sodium fluoride, as this does not completely inhibit glycolysis, particularly in the first hours (44). Moreover, several studies compared results from capillary blood with those of venous blood or plasma; these concentrations can differ considerably, especially in the postprandial state (45). In addition, in some studies the authors did not correct the HemoCue results in whole blood to plasma values. Furthermore, a number of, primarily early, studies used statistical methods with low discriminatory power (e.g. regression analysis, coefficient of variation). In nearly all of the studies, there was a low number of hypoglycemic samples. This has been further complicated by the fact that the device has been used a number of times for neonatal hypoglycemic samples, which are from a very specific patient group, different from adults in several ways. Although one study (46) showed no marked effect of hematocrit on glucose measurements presumably, although not mentioned specifically, in adult blood, it is possible that either hematocrit or other factors in neonatal blood have influenced the results (47). When discussing the data provided by studies on blood glucose measurement, we believe that the accuracy and variability of the reference method used should also be taken into account, as there is no generally accepted gold standard, except perhaps for isotope dilution mass spectrometry. Therefore, a discrepancy between two paired measurements of two devices does not necessarily imply that the tested method is inferior to the reference method used.

In the current study, we have used the YSI as the reference method, as it is a frequently used and well-established analyzer for immediate and accurate glucose determination in research and clinical applications. On the other hand, it has certain disadvantages, not shared by the HemoCue. We have tried to reduce the confounding factors such as type of blood (capillary vs venous), storage of the samples, delay in measurement and conversion to plasma glucose values. Values in the hypoglycemic region, where inaccuracy is most likely to occur and can potentially lead to dangerous clinical situations, were considered specifically. In addition, various methods of analysis with lower and higher discriminatory power have been used, aimed for assessment of accuracy, and in particular to determine how HemoCue compares with the YSI. This study meets the limitations in its focus on the accuracy itself of the HemoCue. It does not describe correlations between venous glucose concentration as determined by a reference method (or the HemoCue) and capillary glucose concentration measured with the HemoCue. Furthermore, the samples analyzed were from adults with hematocrits within a range of 0.38 to 0.51. The results cannot be transposed automatically to determinations in samples with higher (or lower) hematocrits or from neonates.

The results of this study have shown that determination of glucose with the HemoCue system has a very high correlation with measurement with the YSI in a broad range of glycemia, and in hypoglycemia in particular. We believe that these methods can be used interchangeably for research and clinical purposes in adults. However, the criteria of the ADA for blood glucose measuring devices were not met. It must be noted that, for reasons discussed, no statements can be made on accuracy in neonates.

Acknowledgements

This work was supported by a grant from the Dutch Diabetes Research Foundation (no. 96.155). This work is dedicated to the memory of D Willem Erkelen (1941–2004).

References


